The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Metabolism Drugs Market Research Report 2023

Global Metabolism Drugs Market Research Report 2023

Publishing Date : Jan, 2023

License Type :
 

Report Code : 1410850

No of Pages : 90

Synopsis
Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.

Highlights
The global Metabolism Drugs market was valued at US$ 16200 million in 2022 and is anticipated to reach US$ 23350 million by 2029, witnessing a CAGR of 5.3% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
USA is the largest supplier of Metabolism Drugs, with production revenue market share over 43%, while the sales market share is 40%. Europe, following USA, takes production revenue market share of 35% and the sales market share over 23%. That is to say, there are a large number of exports in Europe. Japan is an important market of Drugs for Metabolism Drugs in Asia, accounting for 9% production revenue market share and 10% sales revenue market share of global market.
Players with high-quality products are Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca and Beohrigher Ingelheim, with about 70% market shares.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Metabolism Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolism Drugs.
The Metabolism Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Metabolism Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metabolism Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

By Company

  • Merck
  • Novartis
  • Takeda Pharmaceutical
  • Astra Zeneca
  • Beohrigher Ingelheim
  • KOWA
  • Kythera
  • Fuji yakuhin
  • LG Life Science
  • Metsubishi Tanabe Pharma

Segment by Type

  • Glycogen Metabolism Disease Drug
  • Lipid Metabolism Disease Drug
  • Amino Acid Metabolism Drug
  • Other

Segment by Application

  • Hospital
  • Retail Pharmacy

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia) 
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina, Colombia)

Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Metabolism Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Metabolism Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Index

1 Metabolism Drugs Market Overview
1.1 Product Overview and Scope of Metabolism Drugs
1.2 Metabolism Drugs Segment by Type
1.2.1 Global Metabolism Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Glycogen Metabolism Disease Drug
1.2.3 Lipid Metabolism Disease Drug
1.2.4 Amino Acid Metabolism Drug
1.2.5 Other
1.3 Metabolism Drugs Segment by Application
1.3.1 Global Metabolism Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Global Metabolism Drugs Market Size Estimates and Forecasts
1.4.1 Global Metabolism Drugs Revenue 2018-2029
1.4.2 Global Metabolism Drugs Sales 2018-2029
1.4.3 Global Metabolism Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Metabolism Drugs Market Competition by Manufacturers
2.1 Global Metabolism Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Metabolism Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Metabolism Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Metabolism Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Metabolism Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Metabolism Drugs, Product Type & Application
2.7 Metabolism Drugs Market Competitive Situation and Trends
2.7.1 Metabolism Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Metabolism Drugs Players Market Share by Revenue
2.7.3 Global Metabolism Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Metabolism Drugs Retrospective Market Scenario by Region
3.1 Global Metabolism Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Metabolism Drugs Global Metabolism Drugs Sales by Region: 2018-2029
3.2.1 Global Metabolism Drugs Sales by Region: 2018-2023
3.2.2 Global Metabolism Drugs Sales by Region: 2024-2029
3.3 Global Metabolism Drugs Global Metabolism Drugs Revenue by Region: 2018-2029
3.3.1 Global Metabolism Drugs Revenue by Region: 2018-2023
3.3.2 Global Metabolism Drugs Revenue by Region: 2024-2029
3.4 North America Metabolism Drugs Market Facts & Figures by Country
3.4.1 North America Metabolism Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Metabolism Drugs Sales by Country (2018-2029)
3.4.3 North America Metabolism Drugs Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Metabolism Drugs Market Facts & Figures by Country
3.5.1 Europe Metabolism Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Metabolism Drugs Sales by Country (2018-2029)
3.5.3 Europe Metabolism Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Metabolism Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Metabolism Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Metabolism Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Metabolism Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Metabolism Drugs Market Facts & Figures by Country
3.7.1 Latin America Metabolism Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Metabolism Drugs Sales by Country (2018-2029)
3.7.3 Latin America Metabolism Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Metabolism Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Metabolism Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Metabolism Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Metabolism Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Metabolism Drugs Sales by Type (2018-2029)
4.1.1 Global Metabolism Drugs Sales by Type (2018-2023)
4.1.2 Global Metabolism Drugs Sales by Type (2024-2029)
4.1.3 Global Metabolism Drugs Sales Market Share by Type (2018-2029)
4.2 Global Metabolism Drugs Revenue by Type (2018-2029)
4.2.1 Global Metabolism Drugs Revenue by Type (2018-2023)
4.2.2 Global Metabolism Drugs Revenue by Type (2024-2029)
4.2.3 Global Metabolism Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Metabolism Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Metabolism Drugs Sales by Application (2018-2029)
5.1.1 Global Metabolism Drugs Sales by Application (2018-2023)
5.1.2 Global Metabolism Drugs Sales by Application (2024-2029)
5.1.3 Global Metabolism Drugs Sales Market Share by Application (2018-2029)
5.2 Global Metabolism Drugs Revenue by Application (2018-2029)
5.2.1 Global Metabolism Drugs Revenue by Application (2018-2023)
5.2.2 Global Metabolism Drugs Revenue by Application (2024-2029)
5.2.3 Global Metabolism Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Metabolism Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Metabolism Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck Metabolism Drugs Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Metabolism Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novartis Metabolism Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Takeda Pharmaceutical
6.3.1 Takeda Pharmaceutical Corporation Information
6.3.2 Takeda Pharmaceutical Description and Business Overview
6.3.3 Takeda Pharmaceutical Metabolism Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Takeda Pharmaceutical Metabolism Drugs Product Portfolio
6.3.5 Takeda Pharmaceutical Recent Developments/Updates
6.4 Astra Zeneca
6.4.1 Astra Zeneca Corporation Information
6.4.2 Astra Zeneca Description and Business Overview
6.4.3 Astra Zeneca Metabolism Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Astra Zeneca Metabolism Drugs Product Portfolio
6.4.5 Astra Zeneca Recent Developments/Updates
6.5 Beohrigher Ingelheim
6.5.1 Beohrigher Ingelheim Corporation Information
6.5.2 Beohrigher Ingelheim Description and Business Overview
6.5.3 Beohrigher Ingelheim Metabolism Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Beohrigher Ingelheim Metabolism Drugs Product Portfolio
6.5.5 Beohrigher Ingelheim Recent Developments/Updates
6.6 KOWA
6.6.1 KOWA Corporation Information
6.6.2 KOWA Description and Business Overview
6.6.3 KOWA Metabolism Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 KOWA Metabolism Drugs Product Portfolio
6.6.5 KOWA Recent Developments/Updates
6.7 Kythera
6.6.1 Kythera Corporation Information
6.6.2 Kythera Description and Business Overview
6.6.3 Kythera Metabolism Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Kythera Metabolism Drugs Product Portfolio
6.7.5 Kythera Recent Developments/Updates
6.8 Fuji yakuhin
6.8.1 Fuji yakuhin Corporation Information
6.8.2 Fuji yakuhin Description and Business Overview
6.8.3 Fuji yakuhin Metabolism Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Fuji yakuhin Metabolism Drugs Product Portfolio
6.8.5 Fuji yakuhin Recent Developments/Updates
6.9 LG Life Science
6.9.1 LG Life Science Corporation Information
6.9.2 LG Life Science Description and Business Overview
6.9.3 LG Life Science Metabolism Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 LG Life Science Metabolism Drugs Product Portfolio
6.9.5 LG Life Science Recent Developments/Updates
6.10 Metsubishi Tanabe Pharma
6.10.1 Metsubishi Tanabe Pharma Corporation Information
6.10.2 Metsubishi Tanabe Pharma Description and Business Overview
6.10.3 Metsubishi Tanabe Pharma Metabolism Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Metsubishi Tanabe Pharma Metabolism Drugs Product Portfolio
6.10.5 Metsubishi Tanabe Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Metabolism Drugs Industry Chain Analysis
7.2 Metabolism Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Metabolism Drugs Production Mode & Process
7.4 Metabolism Drugs Sales and Marketing
7.4.1 Metabolism Drugs Sales Channels
7.4.2 Metabolism Drugs Distributors
7.5 Metabolism Drugs Customers
8 Metabolism Drugs Market Dynamics
8.1 Metabolism Drugs Industry Trends
8.2 Metabolism Drugs Market Drivers
8.3 Metabolism Drugs Market Challenges
8.4 Metabolism Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Metabolism Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Metabolism Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Metabolism Drugs Market Competitive Situation by Manufacturers in 2022
Table 4. Global Metabolism Drugs Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Metabolism Drugs Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Metabolism Drugs Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Metabolism Drugs Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Metabolism Drugs Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Metabolism Drugs, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Metabolism Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Metabolism Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Metabolism Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Metabolism Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolism Drugs as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Metabolism Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Metabolism Drugs Sales by Region (2018-2023) & (K Units)
Table 18. Global Metabolism Drugs Sales Market Share by Region (2018-2023)
Table 19. Global Metabolism Drugs Sales by Region (2024-2029) & (K Units)
Table 20. Global Metabolism Drugs Sales Market Share by Region (2024-2029)
Table 21. Global Metabolism Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Metabolism Drugs Revenue Market Share by Region (2018-2023)
Table 23. Global Metabolism Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Metabolism Drugs Revenue Market Share by Region (2024-2029)
Table 25. North America Metabolism Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Metabolism Drugs Sales by Country (2018-2023) & (K Units)
Table 27. North America Metabolism Drugs Sales by Country (2024-2029) & (K Units)
Table 28. North America Metabolism Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Metabolism Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Metabolism Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Metabolism Drugs Sales by Country (2018-2023) & (K Units)
Table 32. Europe Metabolism Drugs Sales by Country (2024-2029) & (K Units)
Table 33. Europe Metabolism Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Metabolism Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Metabolism Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Metabolism Drugs Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Metabolism Drugs Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Metabolism Drugs Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Metabolism Drugs Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Metabolism Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Metabolism Drugs Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Metabolism Drugs Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Metabolism Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Metabolism Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Metabolism Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Metabolism Drugs Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Metabolism Drugs Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Metabolism Drugs Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Metabolism Drugs Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Metabolism Drugs Sales (K Units) by Type (2018-2023)
Table 51. Global Metabolism Drugs Sales (K Units) by Type (2024-2029)
Table 52. Global Metabolism Drugs Sales Market Share by Type (2018-2023)
Table 53. Global Metabolism Drugs Sales Market Share by Type (2024-2029)
Table 54. Global Metabolism Drugs Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Metabolism Drugs Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Metabolism Drugs Revenue Market Share by Type (2018-2023)
Table 57. Global Metabolism Drugs Revenue Market Share by Type (2024-2029)
Table 58. Global Metabolism Drugs Price (USD/Unit) by Type (2018-2023)
Table 59. Global Metabolism Drugs Price (USD/Unit) by Type (2024-2029)
Table 60. Global Metabolism Drugs Sales (K Units) by Application (2018-2023)
Table 61. Global Metabolism Drugs Sales (K Units) by Application (2024-2029)
Table 62. Global Metabolism Drugs Sales Market Share by Application (2018-2023)
Table 63. Global Metabolism Drugs Sales Market Share by Application (2024-2029)
Table 64. Global Metabolism Drugs Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Metabolism Drugs Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Metabolism Drugs Revenue Market Share by Application (2018-2023)
Table 67. Global Metabolism Drugs Revenue Market Share by Application (2024-2029)
Table 68. Global Metabolism Drugs Price (USD/Unit) by Application (2018-2023)
Table 69. Global Metabolism Drugs Price (USD/Unit) by Application (2024-2029)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Metabolism Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Merck Metabolism Drugs Product
Table 74. Merck Recent Developments/Updates
Table 75. Novartis Corporation Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Metabolism Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 78. Novartis Metabolism Drugs Product
Table 79. Novartis Recent Developments/Updates
Table 80. Takeda Pharmaceutical Corporation Information
Table 81. Takeda Pharmaceutical Description and Business Overview
Table 82. Takeda Pharmaceutical Metabolism Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 83. Takeda Pharmaceutical Metabolism Drugs Product
Table 84. Takeda Pharmaceutical Recent Developments/Updates
Table 85. Astra Zeneca Corporation Information
Table 86. Astra Zeneca Description and Business Overview
Table 87. Astra Zeneca Metabolism Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 88. Astra Zeneca Metabolism Drugs Product
Table 89. Astra Zeneca Recent Developments/Updates
Table 90. Beohrigher Ingelheim Corporation Information
Table 91. Beohrigher Ingelheim Description and Business Overview
Table 92. Beohrigher Ingelheim Metabolism Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 93. Beohrigher Ingelheim Metabolism Drugs Product
Table 94. Beohrigher Ingelheim Recent Developments/Updates
Table 95. KOWA Corporation Information
Table 96. KOWA Description and Business Overview
Table 97. KOWA Metabolism Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 98. KOWA Metabolism Drugs Product
Table 99. KOWA Recent Developments/Updates
Table 100. Kythera Corporation Information
Table 101. Kythera Description and Business Overview
Table 102. Kythera Metabolism Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 103. Kythera Metabolism Drugs Product
Table 104. Kythera Recent Developments/Updates
Table 105. Fuji yakuhin Corporation Information
Table 106. Fuji yakuhin Description and Business Overview
Table 107. Fuji yakuhin Metabolism Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 108. Fuji yakuhin Metabolism Drugs Product
Table 109. Fuji yakuhin Recent Developments/Updates
Table 110. LG Life Science Corporation Information
Table 111. LG Life Science Description and Business Overview
Table 112. LG Life Science Metabolism Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 113. LG Life Science Metabolism Drugs Product
Table 114. LG Life Science Recent Developments/Updates
Table 115. Metsubishi Tanabe Pharma Corporation Information
Table 116. Metsubishi Tanabe Pharma Description and Business Overview
Table 117. Metsubishi Tanabe Pharma Metabolism Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. Metsubishi Tanabe Pharma Metabolism Drugs Product
Table 119. Metsubishi Tanabe Pharma Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Metabolism Drugs Distributors List
Table 123. Metabolism Drugs Customers List
Table 124. Metabolism Drugs Market Trends
Table 125. Metabolism Drugs Market Drivers
Table 126. Metabolism Drugs Market Challenges
Table 127. Metabolism Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Metabolism Drugs
Figure 2. Global Metabolism Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Metabolism Drugs Market Share by Type in 2022 & 2029
Figure 4. Glycogen Metabolism Disease Drug Product Picture
Figure 5. Lipid Metabolism Disease Drug Product Picture
Figure 6. Amino Acid Metabolism Drug Product Picture
Figure 7. Other Product Picture
Figure 8. Global Metabolism Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global Metabolism Drugs Market Share by Application in 2022 & 2029
Figure 10. Hospital
Figure 11. Retail Pharmacy
Figure 12. Global Metabolism Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Metabolism Drugs Market Size (2018-2029) & (US$ Million)
Figure 14. Global Metabolism Drugs Sales (2018-2029) & (K Units)
Figure 15. Global Metabolism Drugs Average Price (USD/Unit) & (2018-2029)
Figure 16. Metabolism Drugs Report Years Considered
Figure 17. Metabolism Drugs Sales Share by Manufacturers in 2022
Figure 18. Global Metabolism Drugs Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Metabolism Drugs Players: Market Share by Revenue in 2022
Figure 20. Metabolism Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Metabolism Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Metabolism Drugs Sales Market Share by Country (2018-2029)
Figure 23. North America Metabolism Drugs Revenue Market Share by Country (2018-2029)
Figure 24. U.S. Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Metabolism Drugs Sales Market Share by Country (2018-2029)
Figure 27. Europe Metabolism Drugs Revenue Market Share by Country (2018-2029)
Figure 28. Germany Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Metabolism Drugs Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Metabolism Drugs Revenue Market Share by Region (2018-2029)
Figure 35. China Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Philippines Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Latin America Metabolism Drugs Sales Market Share by Country (2018-2029)
Figure 46. Latin America Metabolism Drugs Revenue Market Share by Country (2018-2029)
Figure 47. Mexico Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Brazil Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Argentina Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa Metabolism Drugs Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa Metabolism Drugs Revenue Market Share by Country (2018-2029)
Figure 52. Turkey Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. U.A.E Metabolism Drugs Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of Metabolism Drugs by Type (2018-2029)
Figure 56. Global Revenue Market Share of Metabolism Drugs by Type (2018-2029)
Figure 57. Global Metabolism Drugs Price (USD/Unit) by Type (2018-2029)
Figure 58. Global Sales Market Share of Metabolism Drugs by Application (2018-2029)
Figure 59. Global Revenue Market Share of Metabolism Drugs by Application (2018-2029)
Figure 60. Global Metabolism Drugs Price (USD/Unit) by Application (2018-2029)
Figure 61. Metabolism Drugs Value Chain
Figure 62. Metabolism Drugs Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’